The gold standard growth hormone secretagogue stack. CJC-1295 (Mod GRF 1-29) mimics natural GHRH pulsatile release while Ipamorelin amplifies the GH pulse without spiking cortisol or prolactin. The result: optimized GH output for sleep quality, body recomposition, recovery, and anti-aging—without the side effect profile of direct GH administration.
CJC-1295 increased mean GH levels by 46% and IGF-1 levels by 45% over baseline in a 2006 dose-escalation study.
Teichman et al., Journal of Clinical Endocrinology & Metabolism, 2006
| Molecular Formula | CJC: C152H252N44O42 / Ipa: C38H49N9O5 |
| Structure | CJC: 29-aa GHRH analog / Ipa: pentapeptide GHRP |
| Half-Life | CJC-1295 (no DAC): ~30 min / Ipamorelin: ~2 hours |
| Administration | Subcutaneous injection |
| Legal Status | Category 1 / Category 2 |
| Power Rating | 4/5 |
CJC-1295 (Mod GRF 1-29) is a modified growth hormone-releasing hormone (GHRH) analog with four amino acid substitutions that resist enzymatic degradation. It stimulates GH release at the pituitary. Ipamorelin is a selective growth hormone secretagogue receptor (GHS-R) agonist that amplifies GH pulses. Together, they create a synergistic GH release that mimics natural pulsatile patterns without desensitizing receptors.
CJC-1295 has Phase I/II clinical trial data demonstrating dose-dependent GH and IGF-1 elevation with good tolerability. Ipamorelin has been studied in multiple clinical trials for post-surgical GI recovery and GH deficiency. The combination is one of the most popular GH optimization protocols in clinical practice and is commonly prescribed by anti-aging and sports medicine practitioners through 503A compounding pharmacies.
Common side effects include injection site reactions, water retention, tingling or numbness in extremities, and vivid dreams (related to enhanced deep sleep). CJC-1295 specifically avoids the cortisol and prolactin elevation seen with other GHRH analogs like GHRP-6. Ipamorelin is considered the cleanest GH secretagogue due to its selectivity for the ghrelin receptor.
CJC-1295 is Category 1 (cleared). Ipamorelin is Category 2 (restricted) with ongoing PCAC review and litigation. The combination is widely prescribed through 503A compounding pharmacies. Research chemical forms are available from specialized vendors.
All vendors listed sell products labeled strictly for research purposes only.